Acute treatment for ischemic stroke in 2004.
The last decade witnessed significant and unprecedented advances in the treatment of acute ischemic stroke. Intravenous tissue plasminogen activator and defibrinogenating agent are both now approved by the Food and Drug Administration for treatment of acute ischemic stroke within 3 h of symptom onset. Trials involving intra-arterial thrombolysis have demonstrated clinical benefit in patients treated within 6 h of symptom onset. The future for the development of new and better treatment for ischemic stroke looks very promising. Currently, induced hypothermia, laser evaporation, mechanical thrombectomy, angioplasty with stent placement, the combination of neuroprotective agents with thrombolysis, and the combination of intravenous with intra-arterial thrombolysis are being investigated.
Mohammad
Yousef M
YM
Department of Neurology, Ohio State University, Columbus, Ohio, USA.
Divani
Afshin A
AA
Kirmani
Jawad F
JF
Harris-Lane
Pansy
P
Qureshi
Adnan I
AI
D000925:Anticoagulants / Q000627:therapeutic use; D002545:Brain Ischemia / Q000628:therapy*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007036:Hypothermia, Induced; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000628:therapy*; D017131:Thrombectomy; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator